Salesforce.com (CRM) Rises But Trails Market: What Investors Should Know

Salesforce (CRM) closed at $248.29, up 1% but trailing the S&P 500's daily gain, and notably underperformed over the past month with an 8.17% loss against a gaining market. The company is set to report earnings on September 3, 2025, with consensus estimates forecasting an 8.2% EPS growth to $2.77 and 8.66% revenue growth to $10.13 billion. While holding a Zacks Rank of #3 (Hold) with stagnant recent EPS estimates, CRM trades at a forward P/E of 21.76 and a PEG ratio of 1.69, both at a discount to its industry averages, indicating a potentially favorable valuation relative to its peers despite recent stock weakness.

Analysis

Salesforce (CRM) exhibits a conflicting profile of recent market underperformance against a backdrop of stable growth expectations and attractive valuation. While the stock's 1% daily gain trailed major indices, its more significant 8.17% loss over the past month starkly contrasts with the S&P 500's 1.1% gain and its sector's marginal 0.05% loss, indicating specific weakness. Forward-looking consensus estimates, however, remain solid, projecting 8.2% EPS growth to $2.77 and 8.66% revenue growth to $10.13 billion for the upcoming quarter. This growth narrative is tempered by stagnant analyst EPS estimates over the last month, culminating in a neutral Zacks Rank of #3 (Hold). From a valuation perspective, CRM appears compelling, trading at a Forward P/E of 21.76 and a PEG ratio of 1.69, both of which represent a discount to the Computer - Software industry averages of 24.96 and 2.0, respectively. This suggests the recent price depreciation may have created a valuation opportunity if the company can deliver on its growth forecasts.

Key Decisions for Investors

• Given the stock's 8.17% monthly decline, investors may find the current valuation attractive, as its Forward P/E of 21.76 and PEG of 1.69 are both at a discount to industry peers.
• The upcoming September 3rd earnings report is a critical catalyst; a beat on the consensus estimates for 8.2% EPS growth and 8.66% revenue growth could reverse the recent negative stock performance.
• The stagnant analyst estimates and Zacks #3 (Hold) rating suggest a wait-and-see approach, so investors should monitor for any positive estimate revisions, which would signal improving fundamentals and could precede a price recovery.